Although preclinical studies in colon cancer models show that IDO1 inhibition can enhance T cell infiltration when combined with anti–CTLA-4 therapy (125, 126), clinical trials of IDO1 monotherapy have demonstrated limited efficacy (127), reflecting tumor-specific metabolic adaptations and compensatory mechanisms. Here, IDO1 is linked to neoplasm.